[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652541":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":57,"collaborators":25,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":25,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":25,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":25,"overallStatus":79,"whyStopped":25,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"University of Florida","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants who receive a transdermal cannabidiol cream","EXPERIMENTAL","Dosing is three pumps per application which delivers approximately one point five milliliters of cream. Application is once daily to the most tender plantar fascia region for the entire study month",[13],"Drug: transdermal CBD cream (Tolcylen®, Marlinz Pharma)",{"label":15,"type":16,"description":11,"interventionNames":17},"Participants who receive a matched placebo","PLACEBO_COMPARATOR",[18],"Drug: Matched Placebos",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","transdermal CBD cream (Tolcylen®, Marlinz Pharma)","The active product is the study CBD cream supplied by the manufacturer. Dosing is three pumps per application which delivers approximately one point five milliliters of cream. Application is once daily to the most tender plantar fascia region for the entire study month. The first dose will be taught and supervised in clinic using a glove. The cream will be massaged into the affected area for at least forty-five seconds. Skin must be clean and dry before application. No other topical agents may be placed on the study area during the study period.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Matched Placebos","The control group will receive a placebo cream identical in appearance, texture, scent, and packaging to the active product but containing no cannabidiol.",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Antony Merendino, DPM","CONTACT","352-273-7044","merena@ortho.ufl.edu",{"name":37,"role":33,"phone":38,"phoneExt":25,"email":39},"Shea Herlihy, MS","352-273-7361","herliso@ortho.ufl.edu",[41],{"facility":42,"status":25,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"University of Florida Department of Orthopaedics","Gainesville","Florida","32611","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-82.32483,29.65163,{"lat":52,"lon":51},[55,56],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},{"name":37,"role":33,"phone":38,"phoneExt":25,"email":39},{"type":58,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100652541","phase-1-a-double-blinded-study-on-rapid-and-sustained-pain-relief-topical-cannabidiol-for-plantar-fasciitis-100652541",false,"NCT07776405","A Double-Blinded Study on Rapid and Sustained Pain Relief Topical Cannabidiol for Plantar Fasciitis","Topical Cannabidiol for Plantar Fasciitis: A Double-Blinded Study on Rapid and Sustained Pain Relief","Inclusion Criteria:\n\n* Patients aged 18-85\n* Clinical diagnosis of plantar fasciitis by a qualified provider\n* Symptomatic for at least four weeks with plantar heel pain consistent with plantar fascia involvement\n* Baseline average pain score that meets eligibility threshold as defined in the protocol (?)\n* Willing to apply assigned cream once daily and attend needed visits (?)\n\nExclusion Criteria:\n\n* Special populations and consent limitations. Pregnancy, breastfeeding, prisoners, inability to provide informed consent, or inability to complete study procedures\n* Contraindications to topical products or CBD. History of allergy or sensitivity to cannabinoids, excipients, or topical creams used in the study\n* Confounding dermatologic conditions at the application site. Open wounds, active infection, dermatitis, ulceration, or recent burns on the heel or midfoot\n* Recent or planned procedures that alter outcomes. Corticosteroid injection, platelet rich plasma, surgery, immobilization, or shockwave therapy within the protocol washout window\n* Concurrent therapies that confound pain outcomes. Routine use of systemic opioids, regular use of nonsteroidal anti-inflammatory drugs beyond rescue parameters, new analgesic starts during the study, or use of other topical analgesics on the study area",true,"ALL","18 Years","85 Years",{"count":71,"type":72},50,"ESTIMATED","INTERVENTIONAL",[75],"PHASE1","This prospective, double-blinded, placebo-controlled study evaluates the efficacy of a 6000 mg transdermal CBD cream in adults with plantar fasciitis. Fifty participants will apply either CBD or placebo once daily for one month.",[78],"Plantar Fasciitis","NOT_YET_RECRUITING","2026-08-17",{"date":82,"type":83},"2026-08-20","ACTUAL",{"date":85,"type":72},"2026-09-01",{"date":87,"type":72},"2027-03-31",{"name":5,"class":6},1]